Leuprorelin Sandoz (Leuprorelin)

Leuprorelin is a GnRH agonist used in several hormone‑dependent disease pathways.

• Prostate cancer: lowers testosterone to help control tumor growth.
• Endometriosis: suppresses estrogen production to reduce lesion activity and pain.
• Uterine fibroids: decreases ovarian hormone stimulation, leading to fibroid shrinkage.
• Precocious puberty: halts premature activation of the hypothalamic‑pituitary‑gonadal axis.
• Assisted reproduction: creates a controlled hormonal environment for ovarian stimulation and embryo transfer.

• Leuprorelin is a synthetic analogue of GnRH that initially stimulates, then desensitizes pituitary GnRH receptors. This results in a rapid rise followed by a sustained fall in luteinising hormone (LH) and follicle‑stimulating hormone (FSH) secretion, ultimately reducing gonadal sex‑steroid production and limiting hormone‑driven disease processes.

Leuprorelin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Hot flashes: transient feeling of warmth and sweating.
• Injection site reactions: pain, erythema, or swelling at the subcutaneous site.
• Headache: mild to moderate intensity.
• Fatigue: generalized tiredness.
• Nausea: occasional upset stomach.
• Decreased libido: reduced sexual desire.

Serious or Rare Side Effects

• Cardiovascular events: hypertension or thromboembolic episodes.
• Bone loss: increased risk of osteoporosis with long‑term use.
• Severe allergic reactions: anaphylaxis or angioedema.
• Pituitary apoplexy: sudden hemorrhage in the pituitary gland.
• Adrenal insufficiency: impaired cortisol response.
• Severe injection site infection: cellulitis or abscess formation.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly.

• Hormone monitoring: assess LH, FSH and sex‑steroid levels to confirm suppression.
• Cardiovascular assessment: evaluate blood pressure and thrombotic risk.
• Bone health: consider baseline bone mineral density and supplement calcium/vitamin D if needed.
• Liver function: monitor in patients with hepatic impairment.
• Hypersensitivity: avoid in individuals with known allergy to leuprorelin or formulation components.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Leuprorelin can interact with other medications that influence hormonal pathways or cardiovascular risk.

Major Interactions (Avoid)

• Concurrent estrogen‑containing contraceptives: may increase thromboembolic risk.
• Combined use with other GnRH agonists or antagonists: can cause excessive hormonal suppression.
• Strong CYP3A4 inducers: may reduce therapeutic effect (monitor levels).

Moderate Interactions (Monitor Closely)

• Bisphosphonates or denosumab: monitor bone turnover markers.
• Anticoagulants: watch for altered clotting parameters.
• Corticosteroids: may mask signs of adrenal insufficiency.
• QT‑prolonging drugs: observe cardiac rhythm for arrhythmias.